PharmaEngine
4162.TWO
2.86 USD
-0.07
-2.39%
p
Overview
Last close
2.86 usd
Market cap
404.68M usd
52 week high
3.68 usd
52 week low
2.32 usd
Target price
4.01 usd
Valuation
P/E
6.9456
Forward P/E
N/A
Price/Sales
4.7574
Price/Book Value
2.2015
Enterprise Value
215.66M usd
EV/Revenue
2.5342
EV/EBITDA
2.9362
Key financials
Revenue TTM
85.10M usd
Gross Profit TTM
83.46M usd
EBITDA TTM
69.39M usd
Earnings per Share
0.41 usd
Dividend
0.2 usd
Total assets
179.19M usd
Net debt
N/A usd
About
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
- Symbol4162.TWO
- ExchangeTWO
- IsinTW0004162003
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CEOMr. Hong-Ren Wang Ph.D.
- HeadquarterTaipei
- Web sitehttps://www.pharmaengine.com
